|
|
|
Sunday, March 21, 2010 — 1:30 PM, Wilson
|
- Prognostication in Tumors of Soft Tissue and Bone
|
|
Moderator:
|
Christopher D.M. Fletcher, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA
|
|
|
Disclosure:
|
In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. The speakers listed below have indicated they have nothing to disclose.
|
Click the button above to add this event to your Itinerary Planner...
| 1:30 | Grading of Soft Tissue Sarcomas - From Histologic to Molecular Assessment - Jean-Michel Coindre, Institut Bergonie, Bordeaux, France |
| 2:00 | Morphologically Benign Lesions of Soft Tissue and Bone Which Metastasize - What Can We Do? - Andrew L. Folpe, Mayo Clinic, Rochester, MN |
| 2:30 | Discussion |
| 3:00 | Break |
| 3:30 | The Prognostic Role of Immunohistochemistry in Sarcomas - Jason L. Hornick, Brigham & Women's Hospital, Boston, MA |
| 4:00 | Prognostication in GIST - A New Paradigm - Brian P. Rubin, Cleveland Clinic, Cleveland, OH |
| 4:30 | Prognostic and Predictive Molecular Testing in Soft Tissue Sarcomas - Where Do We Stand? - Marc Ladanyi, Memorial Sloan-Kettering Cancer Center, New York, NY |
|
The theme and content of the meeting were chosen and approved by the Society’s officers, taking into account the need to pick a novel theme of both utility and interest to general surgical pathologists as well as subspecialists interested in soft tissue and bone tumors. Better prediction of clinical behavior as well as testing which enhances treatment selection are increasingly important components of the modern 'personalized' approach to the care of patients with sarcoma, but the relative value of the contributions from morphology, immunohistochemistry and molecular genetics continues to evolve. This companion meeting will seek to provide a 'state of the art' overview of prognostication in mesenchymal malignancies. |
|
|
|
